News & Events

 

Presenting the 2018 Seminar Series

 

The LSUHSC Center of Excellence in Cardiovascular Research hosts an exciting Cardiovascular Biology Seminar Series! Renowned scientists from prestigious and innovative institutions visit our Center regularly, sharing ideas and inspiring us to become the best. Please take a moment to view the LSU Health Science Center Medical School – Seminar Calendar. These seminars are golden opportunities to learn and visit with other scientists who aspire with similar interests.

 

To see the full list of presenters, click here.

Downloadable 2018 Seminar Series Poster, (PDF) 

 


2017%208:51:45%20AM

LSUHSC Cardiovascular Center and Novo Biosciences Receive
$1.5 million NIH Grant to Study Myocardial Regeneration

 

New Orleans, LA (August 28, 2017) – LSU Health Cardiovascular Center of Excellence received a grant award from the National Heart, Lung and Blood Institute to research the development, a novel agent, MSI-1346, for therapeutic stimulation of heart regeneration following acute myocardial infarction and heart failure. The grant will provide more than $500,000 in funding over two years to LSUHSC-New Orleans along with Novo Biosciences in Bar Harbor, Maine in ongoing research for the project.

 

To read the full press release, click here.


$1.3 Million Grant to Fund Research on Reducing Cardiac Injury
with the First Drug-Eluting Guidewire

 

New Orleans, LA (August 11, 2017) – Adenopaint, LLC of Atlanta, GA, in conjunction with LSU Health New Orleans Cardiovascular Center of Excellence, has been awarded an SBIR Phase II grant in the amount of $1.3 million over two years by the National Heart, Lung and Blood Institute.

The funding will be used to study the company’s Adenowire, a novel guidewire coated with a drug which is released during percutaneous coronary intervention (PCI) to prevent and reverse vascular and cardiac tissue injury during PCI and therefore improve outcomes in cardiovascular diseases.

 

To read the full press release, click here.

 


$3.7 Million Grant to Fund Research on Novel Drug Targeting Heart Diseases

 

New Orleans, LA (August 11, 2017) – The Exscien Corporation of Louisville, KY, in conjunction with LSU Health New Orleans Cardiovascular Center of Excellence, has been awarded an SBIR Fast-Track grant in the amount of $3.7 million over three years by the National Heart, Lung and Blood Institute. The funding will be used to study the company’s first in a new class of drugs that repairs DNA damage to reduce cardiac tissue injury and improve outcomes in cardiovascular diseases.

2017%209:34:38%20AM

 

To read the full press release, click here.


 

Cardiovascular Center Welcomes, Thomas E. Sharp III, Ph.D.

2017%201:58:41%20PM

Dr. Thomas E. Sharp III joined the Cardiovascular Center of Excellence in July as a Postdoctoral Researcher. Dr. Sharp joins us from Temple University, Lewis Katz School of Medicine where he recieved his Ph.D. while working under reknowned professor, John Elrod, Ph.D.. He will work alongside both Dr. Lefer and Dr. Goodchild to continue ongoing research.


Is Cardioprotection Dead? 

2017%202:53:46%20PM

              David J. Lefer, Ph.D., along with Eduardo Marban, M.D., Ph.D., co-authored the latest abstract titled, 'Is Cardioprotection Dead?', issued by the American Heart Association's Circulation as part of their July 2017 issue. 

Acknowledgments were also given to CV Students David J. Polhemus, Ph.D. and Rishi Trivedi, Ph.D. for their laboratory research.

 

The Abstract Summary

"For >4 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of lethal injury. Despite promising initial results and decades of investigation by the cardiology research community, the only treatment with proven efficacy is early reperfusion of the occluded coronary artery. The remarkable record of failure has led us and others to wonder if cardioprotection is dead. The path to translation, like the ascent to Everest, is certainly littered with corpses. We do, however, highlight a therapeutic principle that provides a glimmer of hope: cellular postconditioning. Administration of cardiosphere-derived cells after reperfusion limits infarct size measured acutely, while providing long-term structural and functional benefits. The recognition that cell therapy may be cardioprotective, and not just regenerative, merits further exploration before we abandon the pursuit entirely."

 

2017%203:02:20%20PM 2017%203:02:51%20PM

 

Click to view the full publication

 

Source

David J. Lefer, PhD; Eduardo Marbán, MD, PhD, Is Cardioprotection Dead? American Heart Association,  2017 Jul 4;136(1):98-109. doi: 10.1161/CIRCULATIONAHA.116.027039.
 


Dr. Wu Shares Insight on iPSCs for Cardiovascular Precision Medicine

                Dr. Joseph C. Wu, Professor of Medicine and Radiology; Director of Stanford Cardiovascular Institute; Simon H. Stertzer Endowed Professorship from Stanford University School of Medicine presented the seminar on Induced pluripotent stem cells in cardiology, ‘iPSCs for Cardiovascular Precision Medicine’.

2017%2012:12:48%20PM 

His presentation served as the 5th installment of the Cardiovascular Center of Excellence 2017 Seminar Series. During his visit in New Orleans, Dr. Wu met with LSUHSC professors and postdocs to discuss ongoing projects and potential collaborations.

 

His seminar covered a wide-range of topics discussing iPSC usage such as organ structure and function, patient phenotype, DNA sequence, gene expression and more. To learn more about Dr. Wu’s research, visit Nature Reviews – Cardiology.

 

2017%2012:13:34%20PM
 

Join us for our next Seminar Series guest, Dr. Christopher Kevil, Vice Chancellor of Research; Director of the Center for Cardiovascular Diseases and Sciences; Professor of Pathology at LSU Health Shreveport on Tuesday, August 8th!

 


Cardiovascular Center Faculty Published in Angewandte Chemie International

2017%2012:18:19%20PM

 

                The combined research efforts by the Cardiovascular Center faculty contributed to the manuscript, ‘A Novel Esterase-sensitive Prodrug Approach for Controllable Delivery of Persulfide Species’, being accepted in the Angewandte Chemie International 2017 Edition.

Center faculty David J. Lefer, PhD; Chelsea L. Organ, PhD; Rishi K. Trivedi, PhD; and Zhen Li all made contributions to the study. The manuscript was peer-reviewed and accepted on July 12, 2017.

 

The Abstract Summary

“A new strategy to deliver a well-defined persulfide species in a biological medium is described herein. Under near physiological conditions, the persulfide prodrug can be activated by an esterase to generate a "hydroxyl methyl persulfide" intermediate, which rapidly collapses to form a defined persulfide. Such persulfide prodrugs can be used either as chemical tools to study persulfide chemistry and biology or for future development as H2S-based therapeutic reagents. Using the persulfide prodrugs developed in this study, the reactivity between S-methyl methanethiosulfonate (MMTS) with persulfide was unambiguously demonstrated. In addition, a representative prodrug exhibited potent cardioprotective effects in a murine model of myocardial ischemia-reperfusion (MI/R) injury with a bell shape therapeutic profile.”

 

Click to view the full publication

 

Source

Zheng, Y., Yu, B., Li, Z., Yuan, Z., Lefer, D. J., Wang, B., Wang, S., Organ, C. L. and Trivedi, R. K. (), A Novel Esterase-sensitive Prodrug Approach for Controllable Delivery of Persulfide Species. Angew. Chem. Int. Ed.. Accepted Author Manuscript. doi:10.1002/anie.201704117

 


Newest Faculty Appointment Dr. Papapetropoulos
 

    The Cardiovascular Center of Excellence is proud to welcome Dr. Andreas Papapetropoulos, Ph.D. as the newest faculty appointment. Dr. Papapetropoulos will serve as a full-time professor and Director of the Seminar Series. He comes to us from the National and Kapodistrian University of Athens in Greece. 

Papapetropoulos_headshot

Dr. Andreas Papapetropoulos, Ph.D


Congratulations to our Ph.D Recipients
 

Congratulations to the Cardiovascular Center of Excellence and Pharmacology Graduate Students for receiving their Ph.D.'s and beginning LSUHSC Medical School as part of the incoming 2017 Class:

Polhemus   Organ   2017%2010:20:05%20AM

(Left to Right): Dr. David Polhemus, Ph.D., Dr. Chelsea Organ, Ph.D., and Dr. Rishi Trivedi, Ph.D.

 


Cardiovascular Center Hosts 36th Annual ISHR Conference in New Orleans

     2017%2011:24:59%20AM

      The LSUHSC Cardiovascular Center of Excellence served as the host for the recent 36th Annual International Society for Heart Research - North American Section held at the Hilton New Orleans Riverside from May 30 - June 2. CV Center Director, Dr. David Lefer, served as the meeting organizer and was assisted by CV faculty and staff. 

The meeting was comprised of more than 220 basic and clinical researchers from around the world covering the topic of "Translation of Cardiovascular Therapeutics to the Clinic". The event was a great success and wouldn't have been possible without the combined efforts of the CV Center and several other departments from LSUHSC. Special thanks to Dr. Vander Heide, Dr. Varner, Dr. Kapusta, Dr. Mungrue and Dr. Garder!

Meeting Highlights:

  • Plenary lecture by Eric Olson (UTSW)
  • Janice Pfeffer Distinguished Lecture by Tetsuji Miura (Sapporo Med Ctr)
  • Outstanding Investigator Award lecture by Xander Wehrens (Baylor)
  • Research Achievement Award lecture by Rong Tian (Univ Wash)
  • Peter Harris Distinguished Scientist Award lecture by R. John Solaro (UIC)
  • Dinner Reception/Awards Ceremony and Social at Club XLIV and Encore for conference participants
     

 Dr. Goodchild Named as Ad Hoc Specialist for AAALAC International
 

2017%2011:53:53%20AM

      Dr. Traci Goodchild has been selected to serve a 3 year term as an ad hoc Specialist for AAALAC International. She will travel to different institutions as a site inspector evaluating their compliance with regulatory standards for the care and use of laboratory animals.  There are only 25 out of 377 of AAALAC Specialists that hold only a PhD degree, with the others having been trained as veterinarians. 

2017%2011:55:03%20AM

Dr. Traci Goodchild, Ph.D.